Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 34 min ago
Peer-reviewedCC BY 4.0Frontiers in Immunology

Trajectories of serum hepatitis B surface antigen predict HBeAg clearance in treated children with chronic hepatitis B

  1. 1Department of Hepatopathy Center, Hunan Children’s Hospital, The Affiliated Children’s Hospital of Xiangya School of Medicine, Central South University
  2. 2Key Laboratory of Pathogen-Host Interaction (Tongji University), Ministry of Education, Department of Microbiology and Immunology, Tongji University School of Medicine
  3. 3Department of Maternal and Child Health, Xiangya School of Public Health, Central South University

Abstract

Background: The association between the early dynamics of hepatitis B surface antigen (HBsAg) and its subsequent clearance has been observed in patients with chronic hepatitis B (CHB). However, its relationship with other clinical outcomes remains poorly understood.

Objective: This study aimed to investigate the longitudinal trajectories patterns of HBsAg and their associations with hepatitis B e antigen (HBeAg) clearance in pediatric patients with CHB undergoing antiviral treatment.

Methods: A large retrospective cohort study was conducted on 402 pediatric patients with HBeAg-positive CHB. Latent class trajectory models (LCTM) were applied to examine HBsAg trajectories within the first six months of initiating antiviral therapy. Cox proportional hazard models were used to assess the associations between HBsAg trajectories and HBeAg clearance.

Results: Among the 402 participants, the median age was 5 years, with 249 (61.94%) being male. During a median follow-up of 19.03 months, 216 participants (53.73%) achieved HBeAg clearance. LCTM revealed three distinct HBsAg trajectory patterns: ‘trajectory 1’ (sustained stability, n=43, 10.7%), ‘trajectory 2’ (slow decline, n=195, 48.5%), and ‘trajectory 3’ (rapid decline, n=164, 40.8%). Patients in trajectories 2 and 3 had significantly higher probabilities of HBeAg clearance compared to those in trajectory 1 (adjusted hazard ratio [aHR] = 3.99, 95% CI, 2.20-7.22 for trajectory 2; aHR = 7.21, 95% CI, 3.65-14.24 for trajectory 3).

Conclusions: There is significant heterogeneity in the longitudinal changes of HBsAg levels among pediatric CHB patients with antiviral treatment. Approximately half of the patients exhibited a substantial HBsAg decline, which was associated with a higher likelihood of HBeAg clearance.

Related

  1. Assessing the relationship between chronic aflatoxin exposure and hepatitis B virus immune protection in a population of children receiving nutritional support in Rwanda
    M. A. Matabishi, E. De Rycke, A. Chen +7
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textPlant biologyCrossref
  2. Genetic and autoimmune predispositions to fulminant viral hepatitis in children
    Mohamed Bousfiha, Dalal Ben Sabbahia, Emmanuelle Jouanguy +4
    Frontiers in ImmunologyPeer-reviewedCC BYFull textImmunologyHAL
  3. A capsid hinge region in European hepatitis E virus links mutations to genotype, virion surface properties, and environmental circulation
    Samy Kasmi, Guillaume Sautrey, Cédric Hartard +7
    Applied and Environmental MicrobiologyPeer-reviewedCC BY-NC-ND 4.0Full textProteomics & metabolomicsStructural biologyHAL
  4. The hepatitis E virus ORF2 capsid protein, a cornerstone of viral persistence
    Pierre Bablon, Laura Corneillie, Laurence Cocquerel
    Médecine/SciencesPeer-reviewedCC BY 4.0Full textMicrobiologyHAL
  5. Promyelocytic leukemia (PML) suppresses hepatitis B virus cccDNA transcription through SUMOylation- and SMC5/6-dependent mechanisms
    J. Wu, F. Li, J. Ahodantin +2
    bioRxivPreprintAll rights reservedFull textImmunologybioRxiv
BibTeX
@article{ouyang2026trajectories,
  title = {{Trajectories of serum hepatitis B surface antigen predict HBeAg clearance in treated children with chronic hepatitis B}},
  author = {Wenxian Ouyang and Zhe Ji and Zhenzhen Yao and Songxu Peng},
  journal = {Frontiers in Immunology},
  year = {2026},
  month = nov,
  doi = {10.3389/fimmu.2026.1995382},
  url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1995382/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Trajectories of serum hepatitis B surface antigen predict HBeAg clearance in treated children with chronic hepatitis B
AU  - Wenxian Ouyang
AU  - Zhe Ji
AU  - Zhenzhen Yao
AU  - Songxu Peng
PY  - 2026
DA  - 2026/11/16
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2026.1995382
UR  - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1995382/full
AB  - Background: The association between the early dynamics of hepatitis B surface antigen (HBsAg) and its subsequent clearance has been observed in patients with chronic hepatitis B (CHB). However, its relationship with other clinical outcomes remains poorly understood.  Objective: This study aimed to investigate the longitudinal trajectories patterns of HBsAg and their associations with hepatitis B e antigen (HBeAg) clearance in pediatric patients with CHB undergoing antiviral treatment.  Methods: A large retrospective cohort study was conducted on 402 pediatric patients with HBeAg-positive CHB. Latent class trajectory models (LCTM) were applied to examine HBsAg trajectories within the first six months of initiating antiviral therapy. Cox proportional hazard models were used to assess the associations between HBsAg trajectories and HBeAg clearance.  Results: Among the 402 participants, the median age was 5 years, with 249 (61.94%) being male. During a median follow-up of 19.03 months, 216 participants (53.73%) achieved HBeAg clearance. LCTM revealed three distinct HBsAg trajectory patterns: ‘trajectory 1’ (sustained stability, n=43, 10.7%), ‘trajectory 2’ (slow decline, n=195, 48.5%), and ‘trajectory 3’ (rapid decline, n=164, 40.8%). Patients in trajectories 2 and 3 had significantly higher probabilities of HBeAg clearance compared to those in trajectory 1 (adjusted hazard ratio [aHR] = 3.99, 95% CI, 2.20-7.22 for trajectory 2; aHR = 7.21, 95% CI, 3.65-14.24 for trajectory 3).  Conclusions: There is significant heterogeneity in the longitudinal changes of HBsAg levels among pediatric CHB patients with antiviral treatment. Approximately half of the patients exhibited a substantial HBsAg decline, which was associated with a higher likelihood of HBeAg clearance.
SN  - 1664-3224
ER  -